Clinical Trial Update: Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial is evaluating adding an individualized cancer vaccine to durvalumab, tremelimumab, and chemotherapy in patients with metastatic triple-negative …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• Durvalumab (durvalumab)
• Individualized cancer vaccine
• Tremelimumab (tremelimumab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma | Phase 2 | Status: RECRUITING